The CCNYL1 Knockout NCI-H1299 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population in which the CCNYL1 gene has been disrupted to generate a loss-of-function model. This product comprises a heterogeneous pool of NCI-H1299 cells harboring diverse editing events at the CCNYL1 locus, providing a robust tool for studying the functional consequences of CCNYL1 deficiency without clonal selection artifacts. The polyclonal format preserves the genetic complexity of the parental line while eliminating target gene expression, enabling physiologically relevant assessments of CCNYL1-dependent phenotypes in a lung carcinoma background.
NCI-H1299 is a widely employed human non-small cell lung carcinoma (NSCLC) cell line derived from a lymph node metastasis of a patient with lung adenocarcinoma. These cells are characterized by a TP53-null status and an epithelial morphology, making them a well-established in vitro model for NSCLC research. NCI-H1299 cells are routinely utilized to investigate tumorigenesis, proliferation, apoptosis, and drug response mechanisms, particularly in the context of p53-independent pathways. Their genetic background and metastatic origin render them highly suitable for examining the molecular underpinnings of lung cancer progression and therapeutic resistance.
CCNYL1 encodes a cyclin-like protein belonging to the cyclin family, which is implicated in cell cycle regulation through its predicted ability to interact with cyclin-dependent kinases (CDKs). Mechanistically, CCNYL1 is thought to bind and activate CDK partners such as CDK2 and CDK4, facilitating the phosphorylation of downstream targets including the retinoblastoma protein (Rb). Phosphorylated Rb releases E2F transcription factors, notably E2F1, which then drive the expression of genes required for S-phase entry and cell cycle progression. The activity of CCNYL1 is itself transcriptionally regulated by cell cycle-dependent factors, including members of the E2F family, establishing a regulatory feedback loop within the cyclin-CDK-Rb signaling axis.
In the context of NCI-H1299 cells, which lack functional p53 and exhibit aberrant proliferative control, disruption of CCNYL1 offers a powerful approach to dissect its contribution to unchecked cell division. The TP53-null background accentuates reliance on alternative cell cycle regulatory mechanisms, potentially unmasking the significance of CCNYL1 in maintaining proliferation or survival. This knockout model enables researchers to assess how loss of CCNYL1 impacts Rb phosphorylation, E2F activity, and overall cell cycle distribution, thereby elucidating its role in tumorigenic processes specific to lung adenocarcinoma.
Researchers can apply this polyclonal knockout model in a variety of experimental workflows, including quantitative analysis of cyclin and CDK expression via Western blotting and RT-qPCR, assessment of proliferation rates using BrdU incorporation assays, and cell cycle profiling by flow cytometry. Transcriptome-wide changes upon CCNYL1 loss can be interrogated through RNA-seq, while functional screens for CDK inhibitors or other therapeutics can be performed using drug sensitivity assays. These applications make the CCNYL1 knockout cells valuable for investigating cyclin-CDK interaction networks and cell cycle dysregulation in NSCLC. For additional information or technical support, please contact Ascent Research.
